Aclarion announced the publication of the clinical paper, Establishing a Gold Standard for Noninvasive Identification of Painful Lumbar Discs: Prospective Comparison of Magnetic Resonance Spectroscopy vs Low-Pressure Provocation Discography by the International Journal of Spine Surgery, the official scientific journal of the International Society for the Advancement of Spine Surgery, ISASS. Achieving a result of 100% sensitivity means that in this study if discography indicates a disc is painful, then Nociscan will also indicate that the disc is painful. On the other hand, with a specificity of 80%, this means that when discography indicates a disc is not-painful, Nociscan will disagree 20% of the time by indicating the disc actually contains the biomarkers consistent with a painful disc. Ryan Bond, Chief Strategy Officer, Aclarion stated, “This prospective comparison of Nociscan against the historical benchmark, provocative discography, illustrates powerful conclusions. The authors of the paper have dedicated their careers to advancing the scientific understanding of low back pain pathology, while also striving to improve treatment outcomes. This paper adds to Aclarion’s growing body of evidence for Nociscan as providing valuable information for the non-invasive identification of painful lumbar discs.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ACON:
- Aclarion Announces Closing of $3.0 Million Public Offering
- Aclarion Announces Pricing of $3.0 Million Public Offering
- Aclarion prices 5.175M units at 58c in public offering
- Aclarion, Inc. Clarifies Unfiled Financial Disclosure Status
- Aclarion plans to launch CLARITY trial, provides update on Alphatec partnership